IGF-1 LR3
Long R3 Insulin-like Growth Factor-1
IGF-1 LR3 is a synthetic analog of human insulin-like growth factor 1, engineered with an arginine substitution at position 3 and 13 additional amino acids at the N-terminus. This 83-amino acid peptide exhibits reduced affinity for IGF-binding proteins, resulting in a prolonged half-life of 20-30 hours and approximately 3 times greater potency than native IGF-1. Currently investigational and not FDA-approved for human use.
Complete Dosing Guide
Special Considerations
Blood Sugar Management:
- IGF-1 LR3 mimics insulin and increases glucose uptake into cells.
- Always have carbohydrates available around injection time to prevent hypoglycemia.
- Eat a carbohydrate and protein meal within 30 minutes of injection.
- Monitor for signs of low blood sugar: dizziness, shakiness, weakness, sweating.
Receptor Sensitivity:
- Continuous use beyond 6 weeks can desensitize IGF-1 receptors.
- Cycling is essential to maintain effectiveness.
- Taking breaks allows receptor sensitivity to reset.
- Some users report diminishing returns without proper cycling.
Individual Response:
- Start low and assess tolerance over 1-2 weeks.
- Individual response varies significantly.
- Higher doses don't necessarily mean faster results.
- Pay attention to your body's signals and adjust accordingly.
Stacking Protocols:
- Often combined with growth hormone secretagogues (CJC-1295, Ipamorelin, GHRP-2).
- Can be stacked with recovery peptides (BPC-157, TB-500) for enhanced healing.
- Stacking with HGH creates synergistic effects but requires careful monitoring.
- Always introduce one compound at a time to assess tolerance.
Medical Disclaimer
IGF-1 LR3 is an investigational research compound not approved by the FDA for human therapeutic use. This information is provided for educational purposes only and should not be construed as medical advice. IGF-1 LR3 carries significant risks including severe hypoglycemia and potential tumor growth acceleration. Any use should only occur under strict medical supervision in approved research settings. Individuals with cancer history, diabetes, or other serious medical conditions should not use this compound.